
Delilah F G Hendriks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7736029/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports, 2016, 6, 25187.	1.6	502
2	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Chemical Research in Toxicology, 2016, 29, 1936-1955.	1.7	196
3	Fast and efficient generation of knock-in human organoids using homology-independent CRISPR–Cas9 precision genome editing. Nature Cell Biology, 2020, 22, 321-331.	4.6	170
4	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell, 2021, 28, 816-832.	5.2	133
5	Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Scientific Reports, 2016, 6, 35434.	1.6	118
6	High-Resolution mRNA and Secretome Atlas of Human Enteroendocrine Cells. Cell, 2020, 181, 1291-1306.e19.	13.5	110
7	Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology, 2016, 64, 1743-1756.	3.6	100
8	3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. Biotechnology Journal, 2019, 14, e1800347.	1.8	97
9	CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids. Cell Stem Cell, 2020, 27, 705-731.	5.2	95
10	Establishment of human fetal hepatocyte organoids and CRISPR–Cas9-based gene knockin and knockout in organoid cultures from human liver. Nature Protocols, 2021, 16, 182-217.	5.5	73
11	Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. Tissue Engineering - Part C: Methods, 2018, 24, 534-545.	1.1	69
12	Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. Cells, 2020, 9, 964.	1.8	47
13	Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. Archives of Toxicology, 2018, 92, 557-569.	1.9	35
14	Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Threeâ€Dimensional Spheroid Cultures of Primary Human Hepatocytes. Clinical Pharmacology and Therapeutics, 2020, 108, 844-855.	2.3	31
15	New approach methodologies (NAMs) for human-relevant biokinetics predictions. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 607-622.	0.9	31
16	In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed. Angiogenesis, 2022, 25, 455-470.	3.7	31
17	Human NAD(P)H:quinone Oxidoreductase 1 (NQO1)-Mediated Inactivation of Reactive Quinoneimine Metabolites of Diclofenac and Mefenamic Acid. Chemical Research in Toxicology, 2014, 27, 576-586.	1.7	30
18	Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran. PLoS ONE, 2015, 10, e0138487.	1.1	25

#	Article	IF	CITATIONS
19	Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids. Toxicological Sciences, 2019, 171, 385-395.	1.4	19
20	Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent. Toxicology Letters, 2018, 295, 187-194.	0.4	17